Related Experiment Videos

Pancytopenia induced by low-dose methotrexate. A study of the cases reported to the Finnish Adverse Drug Reaction

T Kuitunen1, J Malmström, E Palva

  • 1Department of Medicine, Helsinki University Central Hospital, Jorvi Hospital, Espoo, Finland. tapio.kuitunen@kolumbus.fi

Scandinavian Journal of Rheumatology
|September 2, 2005
PubMed
Abstract

Insights

Low-dose methotrexate can cause pancytopenia, a serious blood disorder. This condition, particularly in patients with comorbidities or on other medications, is linked to a high mortality rate, often due to infection.

Area of Science:

  • Pharmacology
  • Hematology
  • Rheumatology

Background:

  • Methotrexate is a widely used drug for autoimmune diseases and cancer.
  • Pancytopenia is a rare but severe adverse effect of methotrexate therapy.
  • Understanding risk factors is crucial for patient safety.

Purpose of the Study:

  • To investigate methotrexate-induced pancytopenia.
  • To analyze clinical outcomes and mortality.
  • To identify predisposing factors for bone marrow suppression.

Main Methods:

  • Retrospective review of 18 patient cases of methotrexate-induced pancytopenia.
  • Data collected from a national drug safety agency (1991-1999).
  • Analysis of patient demographics, comorbidities, concomitant medications, and outcomes.

Main Results:

  • The study included 18 patients (median age 72 years) with various conditions like rheumatoid arthritis and psoriasis.
  • 12 patients had major comorbidities, and 16 used concomitant medications.
  • Eight patients (44%) died, primarily from infection; abrupt onset of cytopenia was noted in all.

Conclusions:

  • Methotrexate-induced pancytopenia is associated with significant mortality.
  • High-risk patients include those with comorbidities and on concomitant medications.
  • Prompt recognition and management are vital for improving outcomes.

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...